Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Dude1234 comments on ceo.ca!

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jun 19, 2023 8:55am

170 Views

Post# 35503050

RE:Dude1234 comments on ceo.ca!

Dude is askretka on this board. A good guy and a very good poster who provides tons of DD and grounded and realistic analysis. I believe he thinks Oncy is worth at least $2b usd, and up but shy's away from the bold $15b predictions. Like Noteable, he's a well versed contributor, but Note suggests a b/o price much higher. I tend to agree more with Noteable, especially if/when PDAC & CRC results continue to be unrivaled. I believe Oncy should be priced over $30 right now, not as a per share buyout price. Who knows?

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China